Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지

Genetic Polymorphisms of UGT1A and their Association with Clinical Factors in Healthy Koreans

  • Kim, Jeong-Oh (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) ;
  • Shin, Jeong-Young (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) ;
  • Lee, Myung-Ah (Medical Oncology, Kangnam St. Mary's Hospital) ;
  • Chae, Hyun-Suk (Gastroenterology, Uijeongbu St. Mary's Hospital) ;
  • Lee, Chul-Ho (Department of Clinical Genetics, School of Medicine, Yonsei University) ;
  • Roh, Jae-Sook (KFDA, NITR, Team of Clinical Pharmacology) ;
  • Jin, Sun-Kyung (KFDA, NITR, Team of Clinical Pharmacology) ;
  • Kang, Tae-Sun (KFDA, NITR, Team of Clinical Pharmacology) ;
  • Choi, Jung-Ran (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) ;
  • Kang, Jin-Hyoung (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Glucuronidation by the uridine diphosphateglucuronosy-ltransferase 1A enzymes (UGT1As) is a major pathway for elimination of particular drugs and endogenous substances, such as bilirubin. We examined the relation of eight single nucleotide polymorphisms (SNPs) and haplotypes of the UGT1A gene with their clinical factors. For association analysis, we genotyped the variants by direct sequencing analysis and polymerase chain reaction (PCR) in 218 healthy Koreans. The frequency of UGT1A1 polymorphisms, -3279T>G, -3156G>A, -53 $(TA)_{6>7}$, 211G>A, and 686C>A, was 0.26, 0.12, 0.08, 0.15, and 0.01, respectively. The frequency of -118 $(T)_{9>10}$ of UGT1A9 was 0.62, which was significantly higher than that in Caucasians (0.39). Neither the -2152C>T nor the -275T>A polymorphism was observed in Koreans or other Asians in comparison with Caucasians. The -3156G>A and -53 $(TA)_{6>7}$ polymorphisms of UGT1A were significantly associated with platelet count and total bilirubin level (p=0.01, p=0.01, respectively). Additionally, total bilirubin level was positively correlated with occurrence of the UGT1A9-118 $(T)_{9>10}$ rare variant. Common haplotypes encompassing six UGT1A polymorphisms were significantly associated with total bilirubin level (p=0.01). Taken together, we suggest that determination of the UGT1A1 and UGT1A9 genotypes is clinically useful for predicting the efficacy and serious toxicities of particular drugs requiring glucuronidation.

Keywords

References

  1. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., and Hasegawa, Y. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926
  2. Han, J.Y., Lim, H.S., Shin, E.S., Yoo, Y.K., Park, Y.H., Lee, J.E., Jang, I.J., Lee, D.H., and Lee, J.S. (2006). Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 https://doi.org/10.1200/JCO.2005.03.0239
  3. Innocenti, F., Liu, W., Chen, P., Desai, A.A., Das, S. and Ratain, M.J. (2005). Haplotype of variants in the UDPglucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet. Genomics. 15, 295-301
  4. Innocenti, F., Grimsley, C., Das, S., Ramírez, J., Cheng, C., Kuttab-Boulos, H., Ratain, M.J., and Di Rienzo, A. (2002). Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 12, 725-733 https://doi.org/10.1097/00008571-200212000-00006
  5. Iyer, L., Hall, D., Das, S., Mortell, M.A., Ramirez, J., Kim, S., Di Rienzo, A., and Ratain, M.J. (1999). Phenotypegenotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 https://doi.org/10.1016/S0009-9236(99)70078-0
  6. Jada, S.R., Lim, R., Wong, C.I., Shu, X., Lee, S.C., Zhou, Q., Goh, B.C., and Chowbay, B. (2007). Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98, 1461-1467 https://doi.org/10.1111/j.1349-7006.2007.00541.x
  7. Kiang, T.K., Ensom, M.H., and Chang, T.K. (2005). UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106, 97-132 https://doi.org/10.1016/j.pharmthera.2004.10.013
  8. Mackenzie, P.I., Owens, I.S., Burchell, B., Bock, K.W., Bairoch, A., Bélanger, A., Fournel-Gigleux, S., Green, M., Hum, D.W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Chowdhury, J.R., Ritter, J.K., Schachter, H., Tephly, T.R., Tipton, K.F., and Nebert, D.W. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 7, 255-269 https://doi.org/10.1097/00008571-199708000-00001
  9. Marsh, S., and McLeod, H.L. (2004). Pharmacogenetics of irinotecan toxicity. Pharmacogenetics. 5, 835-843
  10. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, JI., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H., Kubota, K., Yoshida, T., Ohtsu, A., and Saijo, N. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and Genomics. 17, 497-504. https://doi.org/10.1097/FPC.0b013e328014341f
  11. Nowell, S.A., Leakey, J.E., Warren, J.F., Lang, N.P., and Frame, L.T. (1998). Identification of enzymes responsible for the metabolism of heme in human platelets. J. Bio. Chem. 273, 33342-33346 https://doi.org/10.1074/jbc.273.50.33342
  12. Riedy, M., Wang, J.Y., and Miller, A.P. (2000). Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics. 10, 251-260 https://doi.org/10.1097/00008571-200004000-00006
  13. Sandanaraj, E., Jada, S.R., Shu, X., Lim, R., Lee, S.C., Zhou, Q., Zhou, S., Goh, B.D., and Chowbay, B. (2007). Influence of UGT1A9 intronic 1399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J. 1-12
  14. Villeneuve, L., Girard, H., Fortier, L.C., Gagné, J.F., and Guillemette, C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307, 117-128 https://doi.org/10.1124/jpet.103.054072
  15. Yamanaka, H., Nakajima, M., Katoh, M., Hara, Y., Tachibana, O., Yamashita, J., McLeod, H.L., and Yokoi, T. (2004). A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 14, 329-32 https://doi.org/10.1097/00008571-200405000-00008
  16. Ahn, C. (2007). Pharmacogenomics in Drug Discovery and Development. Genomics & Informatics. 5(2), 41-45
  17. Rhu , H.J., Jung, H.Y., Park, J.S., Kim, J.W., Kim, H.T., Park, C.S., Han, B.G., Koh, I.S., Park, C., Kim, K.h., Oh, B.S., and Lee, J.K. (2005). Genetic variants of IL-3 and IL-4 in the Korean population: Polymorphisms, Haplotypes and Linkage Disequilibrium. Genomics & Informatics. 3(4), 149-153